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Background: Both incidence of breast cancer and survival have increased in recent years and there is a need to
review follow up strategies. This study aims to assess the evidence for benefits of follow-up in different settings for
women who have had treatment for early breast cancer.
Method: A systematic review to identify key criteria for follow up and then address research questions. Key criteria
were: 1) Risk of second breast cancer over time - incidence compared to general population. 2) Incidence and
method of detection of local recurrence and second ipsi and contra-lateral breast cancer. 3) Level 1–4 evidence of
the benefits of hospital or alternative setting follow-up for survival and well-being. Data sources to identify criteria
were MEDLINE, EMBASE, AMED, CINAHL, PSYCHINFO, ZETOC, Health Management Information Consortium, Science
Direct. For the systematic review to address research questions searches were performed using MEDLINE (2011).
Studies included were population studies using cancer registry data for incidence of new cancers, cohort studies
with long term follow up for recurrence and detection of new primaries and RCTs not restricted to special
populations for trials of alternative follow up and lifestyle interventions.
Results: Women who have had breast cancer have an increased risk of a second primary breast cancer for at least
20 years compared to the general population. Mammographically detected local recurrences or those detected by
women themselves gave better survival than those detected by clinical examination. Follow up in alternative
settings to the specialist clinic is acceptable to women but trials are underpowered for survival.
Conclusions: Long term support, surveillance mammography and fast access to medical treatment at point of
need may be better than hospital based surveillance limited to five years but further large, randomised controlled
trials are needed.Background
Survival from Breast Cancer has improved markedly in
the last 20 years [1]. This is to be celebrated and has
been attributed mainly to earlier diagnosis and new
treatments to prevent recurrence [2]. Incidence of Breast
Cancer however continues to increase with 47,693 new
cases among women in the UK alone in 2008 [3]. The
lifetime risk of breast cancer for women in the UK is
now 1 in 8. This combined with increased 10 year sur-
vival to over 73% has resulted in an increase in the num-
ber of long term breast cancer survivors so that there
are now over 550,000 women who have been treated for
breast cancer living in the UK [3]. Survivorship after* Correspondence: frances.taggart@warwick.ac.uk
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reproduction in any medium, provided the orBreast Cancer and the medical, psychological and infor-
mational health needs of these patients have become in-
creasingly recognised [4-6]. From the service provision
perspective improved disease free survival reduces the
burden to health services for treatment for advanced
cancer but increases the burden on specialist clinics for
surveillance and for surveillance mammography. There
is also an increased demand for reviewing patients who
refer with potential symptoms of local recurrence or
new cancers which are curable if diagnosed and treated
early.
In this article we have reviewed evidence for best fol-
low up practice worldwide but because health service
provision for the population varies between countries we
have interpreted the evidence in the context of the UK
which has a national health service (NHS) free at the
point of delivery. The main objective of follow up forl Ltd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly cited.
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of patients. These two objectives can sometimes be in
conflict when continued medical examinations have the
potential to cause as well as relieve anxiety and to per-
petuate the patient role. In this context, for example the
value of the annual review and clinical examination of
women who have undergone treatment for early breast
cancer at the specialist hospital clinic has been called
into question [7-10]. The objective of this paper is to re-
view current evidence for women treated for early breast
cancer to inform future follow up strategies.Methods
Criteria for follow up
Criteria were determined by review of a broad range of
literature identified from broad based searches and re-
cent opinion articles and discussion among all three
authors. MEDLINE, EMBASE, AMED, CINAHL, PSY-
CHINFO, ZETOC, Health Management Information
Consortium, Science Direct were all used to search for
these articles.
Key criteria or outcomes determined for the systematic
review were as follows:
1. Risk of second breast cancer over time – incidence
compared to general population (findings in
Additional file 1: Table 1)
2. Incidence and method of detection of local
recurrence and second ipsi and contra-lateral breast
cancer (findings in Additional file 1: Table 2, Table 3)
3. Evidence of the benefits of hospital or alternative
setting follow-up for survival and well-being level 1
– 4 evidence (findings in Additional file 1: Table 4,
Table 5 and Table 6).Searches for review
Searches are reported in Additional file 2 and the Prisma
flow diagrams in Figure 1. We searched Ovid MEDLINE
(R) Daily Update, and Ovid MEDLINE(R) 1948-week3
2011 and Ovid MEDLINE W In-Process and other non-
Indexed Citations up to January 28 2011. For risk of
contralateral cancer observational cohorts and popula-
tion based studies were necessary so large population
based cancer registries were used. For method of detec-
tion of recurrence related to survival, observational stud-
ies from cohorts of patients with long term follow up
were necessary. For follow-up location randomised con-
trolled trials (RCTs) of follow-up measuring survival,
disease free survival, recurrence and quality of life were
retrieved. All searches were from the year 2000 although
one study from 1996 was included by personal commu-
nication. No language restrictions were applied. Searches
were performed by FT and selection of articlesindependently confirmed from the title and abstracts by
FT and JD.
Patients included in the review
For all studies only articles reporting studies of women
with stage 1–3 breast cancer who had no distant metas-
tases and were in remission after surgery were reviewed.
Further particulars of patients are described in the
tables.
Eligibility criteria for articles
Eligibility criteria were appropriate for the type of evi-
dence necessary for the different follow-up criteria and
are described among the inclusion criteria for each table.
Manuscripts not meeting the criteria were excluded. For
all tables care was taken to examine articles for possible
selection bias among participants included in the studies
in order to ensure generalisability of findings. For ex-
ample for the reports of incidence of recurrence studies
of special populations such as those of families at
increased risk of cancer were excluded. Large observa-
tional cohorts of patients followed over at least 10 years
with low attrition rates and population based studies
using cancer registry data were suitable for estimating
recurrence rates and incidence of new primaries. In
order to evaluate the effect of interventions randomised
controlled trials (RCTs) were the best evidence. The evi-
dence for different follow-up locations is therefore pre-
sented in three tables according to the type and quality
of evidence, firstly RCTs which include survival as an
outcome, secondly RCTs which include well-being only
as an outcome and thirdly observational studies and
audits. Inclusion and exclusion criteria for each table are
reported in Additional file 3
Management of morbidity
For this section addressing management of morbidity
the subject matter was too broad to review in a system-
atic way in our article but the issues were nevertheless
relevant to follow up. These issues were therefore dis-
cussed in a narrative way.
Results
Study selection
Potential articles for inclusion in the tables were identi-
fied from the titles and abstracts from the searches in
the first instance by FT and full text articles were
retrieved. These and full text articles from other sources
(reference lists of review articles for example) were
examined by FT and JD and those meeting the inclusion
criteria were included in the tables. Details of the selec-
tion of articles are shown in the PRISMA diagram in
Figure 1.
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Figure 1 PRISMA flow chart.
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selected studies and are presented in Additional file 1.
Risk of second breast cancer over time
Additional file 1: Table 1 shows the findings of studies of
the risk for second breast cancer among women treated
for early breast cancer. We chose to use population data
for the systematic search because of the large sized
populations and generalisability of findings. In Chen’s
study [11] based on cancer registry data from 1970 to
1997 in Canada the incidence rate of new breast cancer
was fairly constant regardless of age when the first can-
cer was diagnosed. Compared to the general population
incidence was higher at all ages with standard incidence
ratios (SIR)ranging from 16.4 (95% CI 12.25 to 21.51) in
women aged under 40 to 1.28 (0.88 to 1.80) in women
aged over 80 years.
Gao’s study [12] using the SEER program data showed
cumulative rates for contralateral breast cancer accrued
steadily over 20 years of follow up with 3% at 5 yrs, 6.1%
at 10 yrs, 9.1% at 15 yrs and 12.0% at 20 years again in-
dicating a constant incidence rate over the 20 years fol-
low-up. Black women had a 20% increased risk
compared to non Hispanic white women and women ofother ethnic groups, while Hispanic and other women
had a 10% decreased risk. Women with medullary can-
cer and women aged over 55 had a small increased risk
of a contralateral breast cancer. These rates are all
higher than those expected for the general population.
Soerjomatar [13] has reported a threefold increased in-
cidence of new breast cancers among women who have
had breast cancer in a population in southern Nether-
lands. Standardised incidence ratio (SIR) was 3.5 (3.2-
3.8) among 9199 breast cancer patients diagnosed from
1972 to 2000 when compared to the population. The
risk was higher among women who were premenopausal
when their primary was first diagnosed. For carcinoma
in situ SIR was 3.4 (2.6 to 4.3). SIR for ipsilateral and
contralateral cancers was very similar, 1.9 and 2.0
respectively.
The results of other types of study confirm the find-
ings of the studies reported above. In a systematic review
of earlier studies Chen [14] reported 16 studies of
cohorts of women treated for early breast cancer. Des-
pite differences between studies in methodology and
definitions of new cancers and differences in populations
studied, the articles in Chen’s review consistently showed
an increased incidence of contralateral cancer among
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compared to the general population; incidence rate
ratios were calculated in 9 studies and this ranged from
1.4 to 5.0.
Incidence and method of detection of local recurrence and
second ipsi and contra-lateral breast cancer
The findings for this are presented in Additional file 1:
Table 2 and Table 3. Local recurrence is defined as re-
currence in the same breast or lymph nodes which is
normally a recurrence of the same cancer as the pri-
mary. This is potentially curable with conventional ther-
apies currently in use.
Incidence and method of detection of local recurrence
and survival - reviews Systematic reviews [10,15,16] of
studies which described incidence and method of detec-
tion of recurrence and survival are presented in Add-
itional file 1: Table 2. Many of the early studies included
in the reviews did not distinguish between new primary
cancers and local recurrence although some used hist-
ology to differentiate true recurrence. There is a consen-
sus among the findings of these studies that hazard rates
for salvageable local recurrence increases during the first
two years after surgery, peaks during the third, declines
until the 6th year and then remains constant thereafter
for stage 1 to 3 breast cancers [15,17-19]. A recent study
of 650 patients treated with breast conservation from
1990 to 1997 and followed up indefinitely showed that
loco-regional relapses including contralateral cancers
continued to occur at a steady rate of 1.4% per year for
16 years [20]. Another recent study distinguished local
recurrence from new primaries in the same breast and
reported cumulative incidence of local recurrence as
5.0% (3.9-6.3) at five years, 6.5% (5.2-7.9) at ten years
and 8.7% (6.2-11.6) at 15 years in a cohort of women
treated with radiotherapy [21].
The earliest systematic review of method of detection
of recurrences and new cancers was by Grunfeld [15] in
which there was a wide range in relative percentage of
recurrences detected by mammography (8-50% of cases)
or physical examination (12-88%). Changes through time
in frequency of use of mammography is an issue here.
More recent studies tend to show a smaller proportion
of cancers detected by clinical examination and a larger
number by mammography. Most studies are limited by
the lack of information about the mammography regi-
men and schedule for clinical examination.
Montgomery [10] reviewed twelve studies which mea-
sured relapse after breast conserving surgery and their
method of detection. He analysed these separately in
two groups one before the year 2000 and one after.
Among the eight studies before 2000 46% were detected
by routine clinical examination and only 15% bymammography while after 2000 40% were detected by
mammography and 15% on routine clinical examination.
Both Montgomery [10] and Lu [16] also looked at sur-
vival in their reviews. In Montgomery’s review relapses
detected by mammography and self examination
resulted in better survival at 10 years but this effect had
disappeared by 15 to 20 years. Long term survival data
however was only available for some studies. Lu [16] dis-
tinguished between early (mammographically detected)
and late detection of recurrences in his meta-analysis
and also compared mammographically detected recur-
rence to physical examination. In both cases mammo-
graphic detection gave better survival. This was
confirmed in the recent study by Houssami [22]. Hazard
ratio (HR) for asymptomatic (relative to symptomatic)
detection was 0.51 (0.32-0.80) for Ipsilateral Breast Re-
currence, 0.53 (0.36-0.78) for Contralateral Breast Can-
cer, and 0.53 (0.40-0.72) in all subjects (P< 0.0001).
Montgomery’s [19] own study showed a poorer sur-
vival for clinically detected cancers while the Dutch [23]
and Hong Kong [24] studies found no difference in sur-
vival between different methods of detection but num-
bers involved were smaller than in the meta-analysis by
Lu [16].Method of detection of local recurrence and survival -
articles with report of surveillance mammography
published after year 2000 Since many early studies were
limited by the lack of reporting of the frequency of
mammography, articles with reported mammography
and outpatient schedules were presented in Additional
file 1: Table 3. The frequency with which recurrences
were first detected by mammography was 51% in the
study by Montgomery [19] in which mammography was
annual throughout 10 year follow-up and 43% in the
study by Yau in which mammography was annual for
5 years. Overall clinical examination was more frequent
than mammography, at least every 6 months for the first
five years with the exception of the Montgomery study
in which clinical examination was annual after three
years. The study by Lash [25] was a case control study
comparing survivors with non survivors. All cause mor-
tality rate declined with increasing number of mammo-
grams (test for trend p = 0.007). The age- and therapy-
adjusted odds ratio associating receipt of an additional
mammogram compared with receipt of no mammogram
was 0.77 (95% confidence interval [CI] 0.53-1.1). Despite
annual mammograms for five years and frequent clinical
examination 34% cancers were first detected by the pa-
tient in the study by Montgomery [26] and 9% in the
study by Yau [24]. Implications of this are that self
examination is still important particularly in the first six
years after diagnosis.
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or more after treatment for the primary cancer and
women who have had breast cancer are also at increased
risk of developing a new cancer in the other breast, it is
likely that routine surveillance mammography will be of
benefit in detecting asymptomatic cancers and improv-
ing survival for an indefinite period of time. The weight
of evidence supports surveillance mammography as an
effective means of detecting curable recurrences and
new cancers and that it improves survival. All of these
observational studies of routine clinical practice showed
that some cancers were still detected by clinical examin-
ation. Routine clinical examination still serves as a
“safety net” for women who have not attended for mam-
mography, do not wish to self examine, or have, for
other reasons, failed to report symptoms. It is also pos-
sible that clinicians are more likely to detect recurrence
in the axilla than patients who self examine. For this
type of information comparison of retrospective reports
of survival based on method of detection can be mis-
leading since the method of detection will depend on
the services available, the type of cancer and adequate
recording of data. Slow growing cancers are more likely
to be detected in the preclinical, asymptomatic stage
than fast growing ones and in addition to this there is
the problem of lead time bias. The studies reviewed in
this section measured survival from diagnosis thus
avoiding lead time bias but earlier stage detection of
slow growing cancers is a source of bias that is more dif-
ficult to avoid. In future more precise characterisation of
the tumour by genetic tests and surveillance with MRI
may enable earlier detection than routine mammog-
raphy. In a study among women at high risk of breast
cancer MRI was found to be more sensitive than mam-
mography [27]. To date MRI scanning has not been used
for primary population screening because the specificity
is too low but it can be effective in detecting recurrence
when mammograms are difficult to read particularly
after radiotherapy.
Evidence of the benefits of hospital or alternative setting
follow-up for survival and well-being – level 1-4 evidence
There is controversy regarding the value of specialist fol-
low up in a hospital setting as currently practised for
women who have undergone treatment for early breast
cancer.
Current practice and guidelines The recent guidelines
of the National Institute for Health and Clinical Excel-
lence in the UK (NICE [28] guidelines 2009) recommend
that asymptomatic breast cancer patients who have
undergone curative treatment should have follow-up for
5 years after diagnosis. They also recommend annual
surveillance mammography for 5 years after diagnosisor, for younger women, up to the age when they become
eligible for the routine population screening programme.
A survey of specialist breast care practitioners in the UK
(before the most recent guidelines) by Donnelly [29]
demonstrated that 92% were discharging patients
according to a locally agreed protocol. Decisions about
follow-up were made based on risk of recurrence and
prescribing of aromatase inhibitors or tamoxifen. Clini-
cians felt that the follow-up clinic visit was mainly aimed
at managing side effects of medication in order to maxi-
mise compliance, treating treatment sequelae, detecting
recurrence and new cancers and identifying psycho-
logical problems.
ASCO [30,31] recommend a careful history and phys-
ical examination every 3–6 months for the first three
years, every 6–12 months for the 4th and 5th year and
annually thereafter. They also recommend that in
addition to the physical examination and history physi-
cians should counsel patients about symptoms of recur-
rence and about breast self-examination. Women at
high risk for familial breast cancer syndromes should be
referred for genetic counselling. Pelvic examinations are
also recommended for all women particularly patients
taking Tamoxifen (who are at increased risk of endomet-
rial cancer) and re-referral for oncology assessment for
all women receiving adjuvant endocrine therapy.
RCTs of breast cancer follow-up in hospital or alter-
native settings which include recurrence or survival
as outcomes - level 1 evidence By far the greatest limi-
tation to the validity of these studies (Additional file 1:
Table 4) is the significant number of patients excluded
by the medical staff or breast care nurses because they
considered them unsuitable. Reasons for this were not
always given but it is likely that reasons are related to
clinical issues such as post-surgery problems or per-
ceived risk of relapse or anxiety on the part of the
patient.
The findings need to be interpreted in this context.
Grunfeld’s two studies of hospital follow up compared to
follow-up in General Practice in the UK [32] and in
Canada [33], respectively, provide information on sur-
vival and well-being (18 month and median of 3.5 years
follow up respectively) and show no differences in over-
all survival together with general satisfaction of patients
and no difference in well-being. Grunfeld’s Canadian
study remains the largest study to date reporting recur-
rence and survival endpoints based on an analysis of 968
patients. The studies were, however underpowered and
follow up was too short to evaluate the impact on sur-
vival. Similarly reports of nurse led follow-up in the UK
such as Beaver’s study [34] report high levels of satisfac-
tion but have small numbers of patients. Beaver’s study
had a follow-up period of five years so that long term
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measure time to confirmation of recurrence in hospital
and this was not different in the two groups. In conclu-
sion, data on survival is inadequate and the effects of al-
ternative follow-up on survival remain unknown.
RCTs of breast cancer follow-up in hospital or alter-
native settings with acceptability, well-being, access
to medical care as outcomes - level 1 evidence There
is a consensus among the RCTs of nurse led or General
Practitioner (GP) led alternative follow-up that patient
satisfaction and anxiety is similar or better in alternative
follow-up (Additional file 1: Table 5). The findings indi-
cate no difference in health related quality of life [35-
39]. Patient satisfaction was better in the GP group in
Grunfeld’s study [40]. There was no evidence for
increased use of services in GP follow up in one study
[41]. In the RCT by Sheppard [42] the majority of
patients who had a recurrence in both the point of need
access group and the 6 monthly review group were ad-
mitted via an emergency route. The short symptom his-
tory indicated that it was unlikely that the recurrences
would have been detected at a routine visit.
There is however a paucity of evidence for evaluating
different locations for follow-up. New studies with lim-
ited findings as yet are in progress; a four arm RCT in
the Netherlands comparing hospital and nurse led
follow-up has shown evidence for acceptability by
patients of alternative nurse led follow up but it is too
soon yet for survival evidence [43-45] there is also a
shared care study of GP follow-up in France at the Insti-
tut Curie [46].
Breast cancer follow-up in alternative settings with
acceptability, well-being, access to medical care as
outcomes - observational studies or audits - level 2–4
evidence Evidence from observational studies and audits
to evaluate alternative follow-up compared to hospital
follow-up for outcomes such as well-being and satisfac-
tion and in some cases survival is shown in Additional
file 1: Table 6.
There is also no evidence of increased use of normal
GP services or increased numbers of tests in the alterna-
tive groups where this was investigated. Koinberg [35] in
Sweden has compared costs of routine follow-up by a
physician with nurse led follow up on demand for five
years and found the nurse led follow-up to be less ex-
pensive. Patient satisfaction was high and anxiety low in
both groups.
Evidence regarding the psychological effect of the an-
nual visit itself on the patient is conflicting with some
studies showing that patients are reassured by the visit
and others reporting that it generates anxiety [34]. Ganz
[4] reports that women often report that their fear ofrecurrence increases after active treatment is withdrawn
and they miss the reassurance that ready access to the
health care system can provide. Long term shared care
protocols which incorporate continuity of care for
patients could address many of the medical and psycho-
social needs of patients.
Lash [47] in a USA study of a cohort of stage 1–2
breast cancer patients in five hospitals in Boston com-
pared patients who received USA guideline surveillance
consisting of history taking, clinical examination and
mammography with those who did not. Mortality and
cancer related anxiety were higher among patients who
did not receive surveillance. This persisted after control-
ling for a number of confounding factors such as age,
primary therapy, cardiopulmonary co-morbidity index,
education and other social covariates. This was an obser-
vational study and so the findings may have been
affected by social factors for which it was not possible to
control. Chapman [48] audited a scheme of patient led
follow-up (PLFU) for low risk patients in Cambridge and
found that the scheme was universally well received by
patients and did not significantly increase GP workload.
The PLFU includes an education session for the patient
and an information pack at their follow up discharge
interview and there is also educational material for the
patients’ GPs. 126 (97%) patients had a clear idea of how
to contact the breast unit, and only 5 of 130 patients
(4%) required a breast clinic appointment. Only 10 of
277 GP respondents (3.6%) referred a patient on PLFU
back to the breast unit during the study period. In South
Wales a radiographer led follow up has been piloted
[49]. Under this scheme the patients have a one stop ser-
vice whereby the radiographer goes through a protocol
set of questions and physical examination at the time of
the mammographic surveillance. If there are any pro-
blems there is a fast track referral service to the breast
cancer unit at the hospital.
In Scotland Montgomery [50] assessed the acceptabil-
ity of automated telephone follow up in a feasibility pilot
study of 110 women who attended a routine follow up
clinic between May to August 2006. They found that
71% of the patients found the system easy to use but
only 65% liked it and were happy to use it as their sole
means of follow-up. All of the UK schemes also incorp-
orate telephone access to a specialist breast cancer nurse
and are underpinned by surveillance mammography.
Jiwa [51] in a study of follow up in general practice
found anxiety and depression presented relatively soon
and were often enduring whereas concomitant medical
problems also presented later.
Murray [52] reported a service user designed frame-
work for proactive care for people with cancer in five
General Practices in Scotland. Innovations included an
intranet based register, meetings and information sheets.
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the framework helped achieve continuity of care and
improved support and information for all.
Vanhuyse [53] reported a Canadian programme of
planned discharge to family physician including patient
and also family physician information packages. They re-
port reasons for not transferring. However patients
transferred were still seeing radiologists and surgeons.
In addition to the intervention for alternative follow
up patients in the UK normally have access to a special-
ist breast care nurse for an indefinite period of time after
their operation and this may be helping to reassure
women discharged from hospital follow-up in the UK
studies. The non-randomised evidence of cohorts or ob-
servational studies contributes to the generalisability of
the findings of the RCTs since they are based on a
broader base of patients.
Management of morbidity
Evaluation of symptom oriented detection of distant
metastases with clinical examination versus more intensive
investigations
It is clear that early detection of local recurrence and
early detection of new cancers can improve survival.
However ASCO (2006) [31], NICE (2009) [28], BASO
(2009) [54] and ESMO(2008,2009) [55,56] guidelines are
unanimous in advising against routine search for distant
metastases. There is no advantage in early diagnosis of
distant metastases since there is no evidence that early
treatment is more effective. Evidence for this mainly
comes from a Cochrane review in which the use of in-
tensive surveillance using bone scans and blood tests for
tumour markers in order to search for distant metasta-
ses was evaluated [57]. Within the review two RCTs in-
volving 2563 women compared usual follow up of clinic
visits and mammography with more intensive investiga-
tions [58,59]. The findings were that routine screening
for metastases using MRI scans and blood tests for
tumour markers did not improve survival (hazard ratio
0.96, 95% confidence interval 0.80 to 1.15) or disease-
free survival (hazard ratio 0.84, 95% confidence interval
0.71 to 1.00) or quality of life. Reporting symptoms and
starting treatment when they occur, surveillance mam-
mography and clinical examination were as effective.
There was still no difference in survival after 10 year fol-
lowup in the Roselli del Turco study [59]
Adherence to endocrine therapy and management of side
effects
These treatments are long term preventive therapies and
adherence to endocrine therapy has been cited as one of
the main reasons for hospital led follow-up by hospital
consultants in the UK [60]. In a Dutch study [61] adher-
ence to hormone therapy was better than in the UK andthe authors presumed this was due to five years follow
up as opposed to three in the UK. Chemotherapy and
treatment with Herceptin occurs within the hospital set-
ting prior to discharge to routine surveillance. However
hormone therapy, either tamoxifen or aromatase inhibi-
tors, are being used for increasing periods of time to re-
duce the risk of local recurrence and metastatic disease.
Adjuvant hormonal or chemotherapy has also been
found to considerably reduce the risk of a new contralat-
eral breast cancer primary [62-64]. Numerous trials have
shown the effectiveness of Tamoxifen and aromatase
inhibitors in increasing survival in women with ER+ ve
breast cancer and treatment with tamoxifen and aroma-
tase inhibitors is now standard practice. Ongoing trials
with new drugs will indicate the optimum length and se-
quence of follow-up treatment with different drug com-
binations. Chlebowski [65] performed a systematic
review of 9 trials of adherence to endocrine therapy in
clinical settings. Findings were that in adjuvant breast
cancer clinical trials with greater or equal to 4 years fol-
low-up, hormonal therapy (tamoxifen or aromatase inhi-
bitors) was prematurely discontinued by about 23-28%
of the study participants. Adherence to aromatase inhi-
bitors did not differ from adherence to tamoxifen in this
setting. In breast cancer prevention trials, tamoxifen was
prematurely discontinued by 20-46% of the participants.
In clinical practice settings, only 2 reports addressed
longer-duration (>4 years) adherence to adjuvant tam-
oxifen use. In these, tamoxifen was prematurely discon-
tinued by 30-50% of the patients. Poor tolerance of
treatment adverse effects was reported in older breast
cancer survivors and this predicted mortality at 7 years
follow up in a further recent study by Clough-Gorr [66].
In the light of the effectiveness of these drugs in redu-
cing breast cancer mortality compliance is a problem
which should be addressed in follow up. Reasons for
non-compliance are not clear but side effects are likely
to be one cause. These include the effects of long term
anti-oestrogen therapy such as osteoporosis and possible
effects on lipid metabolism and cardiovascular risk
which should be monitored in all patients. There is a
need for further research in this area.
Interventions to improve well-being among women treated
for early breast cancer
Long term symptoms and after effects of treatment that
women who have had breast cancer can encounter are
well known. Ganz [4-6,67,68] has reported these symp-
toms extensively in several publications including a large
survey of breast cancer survivors 5 to 10 years after
diagnosis. She has recommended a shared care follow-
up plan including a record of treatment to be held by
the patient. Many side effects associated with adjuvant
endocrine therapy can continue for 5–10 years and
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uterine cancer and possibly cerebrovascular events.
Patients on aromatase inhibitors also are at increased
risk of osteoporosis and fractures. Patients also have
long term after effects of systemic therapy. These in-
clude fatigue, ovarian failure, and menopausal symp-
toms, neuropathy, cognitive dysfunction, weight gain,
psychological distress and sexual dysfunction. Late com-
plications include an increased risk of leukemia and an
increased risk of cardiac dysfunction due to anthracy-
clines. There are also long term side effects following
surgery and radiation therapy including numbness,
weakness and arm swelling. Breast pain may result from
radiation therapy in 1% of patients. Anxiety and depres-
sion are also common. Lebel [69,70] followed survivors
in a study of stressors at 5 time points up to 6 yrs post
diagnosis. Cancer concerns were rated as not especially
stressful, with the exception of fear of the future which
was the most stressful of the four concerns on all meas-
urement occasions. Physical limitations and pain were
reported to induce equivalent levels of stress and their
intensities decreased over time. Patients in the UK may
receive medical treatment for these symptoms routinely
through their General Practitioner. The Cochrane review
by Cruickshank [71] revealed that psychosocial nursing
interventions around diagnosis and early treatment
could affect some components of quality of life, such as
anxiety and early recognition of depressive symptoms.
However, their impact on social and functional aspects
of the disease later on was less clear. Physical exercise
seems to be the most effective strategy to combat fatigue
and to improve mood [72-79]. Other interventions in-
volving information and psychosocial support had vari-
able levels of success but most report benefits [38,71,80-
85]. In one trial [86] yoga was found to be effective for
many well-being outcome measures. Information and
support were most effective in the first three months
after diagnosis. The study by Sandgren [38] was a nurse
led telephone intervention incorporating education and
this showed one small effect for perceived stress favour-
ing health education. The psychological intervention by
Andersen [87] reported that survival at 11 years was
improved (recurrence hazards ratio [HR] of 0.55;
P = 0.034) and death from breast cancer (HR of 0.44;
P = 0.016) in addition to improved well-being and com-
pliance with medication.
Discussion
This study has highlighted evidence for follow up strat-
egies that are likely to improve survival and well-being
of women treated for early breast cancer. Follow up
should encompass early detection of new cancers as well
as recurrence and maximise adherence to preventive
endocrine therapy in those patients with oestrogen orprogesterone receptor positive cancers. Evidence that
women with a history of breast cancer are at increased
risk of a second breast cancer primary was confirmed in
large populations with different health care systems.
Long term studies indicate that this increased risk con-
tinues at a constant rate for 20 years or more.
There is evidence from the studies we reviewed that
mammographically detected recurrences are also detected
at an earlier stage and results in better survival than clin-
ically detected ones and that local recurrence may occur
many years after treatment. The finding that a regimen of
surveillance mammography offers a survival benefit
among women treated for primary breast cancer when
compared with a surveillance regimen that does not in-
clude surveillance mammography was also reported in a
recent Health Technology Assessment incorporating a
systematic review [88]. However due to the limited avail-
ability of data the studies reviewed were not randomised
controlled trials and no conclusions could be drawn
about the optimum frequency or duration of mammog-
raphy after surgery. It is also unclear as to what age mam-
mography should be continued. A pragmatic approach is
to only undertake investigations if the findings would
influence clinical decisions. In women over the age of 80
many would elect not to have surgery because of the
higher risks in this age group. If there is already consider-
able comorbidity adding preventive medication with likely
side effects and drug interactions may not be advisable.
There is the potential for harm due to over-surveillance
in this case. In the same way a search for distant metasta-
ses in healthy women treated for early breast cancer is
not advised and this is generally accepted among breast
cancer specialists.
Whilst much of what we know about the benefits and
side effects of breast cancer treatment have been learnt
from long term follow up of cohorts of patients in the
specialist clinic its contribution to improved outcomes
remains unclear. Detection of local recurrence and
contralateral cancers occurs more often by patients or
by surveillance mammography than by routine clinical
examination and hospital based follow up does not meet
patients’ needs for psychosocial support. The increasing
numbers of breast cancer survivors put pressure on ser-
vices that may be better directed to patients who are ill.
Recent debate [89] regarding the possibility of “over
diagnosis” of breast cancer through screening [90] has
highlighted the pivotal role of long term tracking of
cohorts of patients in evaluating the prognosis of small
cancers. It may be possible in the future to identify gen-
etic profiles and patient characteristics which predict a
very low risk. This need not be a reason for hospital led
follow-up; computerised tracking and linking of primary
care records would enable this essential data to be
recorded for research purposes.
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nificant proportion of patients were retained in hospital
follow-up by oncologists [32,33]. It is likely that patients
requiring mastectomies and chemotherapy may not have
completed treatment by one year after diagnosis and
patients may also be retained because of anxiety. Early
discharge to alternative follow up at one year post diag-
nosis is likely to be suitable only for low risk patients
who have had conservative surgery with no complica-
tions or need for reconstruction.
Addressing emotional and physical concerns are im-
portant parts of survivorship which should be incorpo-
rated into any follow-up plan regardless of location.
Ganz recommends a self held care plan. In the UK the
universal population based primary care system includes
general practitioners, practice nurses, district nurses,
health visitors and community psychiatric services which
often work from the same health centres. Patient held
care plans are successfully used for a variety of chronic
conditions as a supplement to the NHS organisational
structures and as an aid to communication.
Generally women reported high satisfaction with alter-
native follow-up regimes. These studies did not report
any consideration of age in the design or interpretation
of the trials or details of how alternative follow-up was
presented to the women and whether survival was dis-
cussed. It is likely that when survival and well-being are
in conflict, such as in making decisions about stressful
tests or preventive treatment which has side effects,
patients may make different choices [66] so that some
inequalities will not depend on service availability. More
research is needed into how well patients understand
risk, how much they are prepared to allow their treating
doctors to make medical decisions on their behalf and
the social differences and circumstances associated with
these choices.
A major issue in follow-up is the management of pre-
ventive hormone therapy. 75% breast cancers are hor-
mone dependent and thus susceptible to hormone
therapy. In a survey of breast cancer specialists in the
UK the management of this therapy was highlighted as
the most important aim of follow-up [29]. Preventive
treatment and the management of chronic disease is typ-
ically the premise of General Practice not the specialist
unit at the hospital. In the light of new preventive treat-
ments available and the need to monitor long term side
effects such as osteoporosis, it is likely that the majority
of this care should be transferred to General Practice
where informational needs for local support networks
and other services could also be more easily met.
A strength of our study is that it is a synthesis of evi-
dence and encompasses a range of important criteria for
breast cancer follow-up both for the survival and well-
being of patients and health service provision. We haveincorporated other more specialised reviews among our
evidence. A limitation is that we have not included an
analysis of cost with the exception of one study where
the evidence was from a randomised controlled trial[35].
We chose not to review other studies based on theoret-
ical models using assumptions for input data.
Conclusions
Long-term support, surveillance mammography and fast
access to medical treatment at point of need may be bet-
ter than hospital based surveillance limited to five years.
Women who have had breast cancer are at increased
risk of a second primary in the long term and this is par-
ticularly important for younger women. The frequency
with which local recurrence is detected by patients be-
tween routine surveillance mammography indicates that
breast self-examination may be important for this group
and a risk adjusted surveillance strategy may be helpful.
Surveillance mammography and transfer to management
in General Practice or a nurse or radiographer led ser-
vice operating from the hospital are acceptable to
patients but adequate data on survival is lacking. Evi-
dence for optimal frequency and duration of surveillance
mammography is inadequate. Further studies with long
term outcomes are needed to establish the safety and ef-
fectiveness of novel alternative options relevant to pa-
tient cohorts stratified for age, tumour biology and
treatment type.
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